Q-omics provides the consensus-scored IGHD5-24 profile across patient tissues and cancer cell-line models. IGHD5-24 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGHD5-24 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, IGHD5-24 RNA expression shows 8,001 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight HNSC, LUSC, and LAML as cancer lineages where IGHD5-24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHD5-24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHD5-24 survival associations across molecular data types. IGHD5-24 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHD5-24 RNA expression–survival associations across cancer types. High IGHD5-24 expression shows unfavorable associations in HNSC, UCEC, TGCT, SKCM and KIRP, but favorable associations in BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for IGHD5-24 RNA expression.
This table summarizes IGHD5-24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for IGHD5-24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHD5-24 shows higher tumor expression in LUSC, LUAD and STAD. The LUSC box plot shows higher IGHD5-24 RNA expression in tumor versus normal tissue (log2 FC = +0.218, t-test p = .011).
This table shows molecular features associated with IGHD5-24 in patient tissues and cancer cell lines. In patient samples, IGHD5-24 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
